CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease...
Phase 2, Phase 3
Austin, Texas, United States and 89 other locations
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's...
Phase 3
Austin, Texas, United States and 75 other locations
progression of AD, as compared to no stimulation (OFF), by measuring baseline (pre-implantation) to 12-month change in the integrated Alzheimer's...
Austin, Texas, United States and 20 other locations
administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's...
Phase 2
Austin, Texas, United States and 96 other locations
be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...
Phase 2
Austin, Texas, United States and 168 other locations
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...
Phase 3
Austin, Texas, United States and 246 other locations
The objective of this study is to determine the safety and tolerability of fosgonimeton (ATH-1017) in subjects with mild to moderate Alzheimer's...
Phase 2, Phase 3
Austin, Texas, United States and 75 other locations
This is a 96-week extension study of open-label simufilam 100 mg b.i.d. for mild-to-moderate Alzheimer's disease subjects who compl...
Phase 2
Austin, Texas, United States and 10 other locations
to alleviate symptoms when given to people with mild to moderate Alzheimer Disease (AD) dementia. This is done by looking at partic...
Phase 2
Austin, Texas, United States and 44 other locations
study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's...
Phase 2
Austin, Texas, United States and 202 other locations
Clinical trials
Research sites
Resources
Legal